JG
MYGN icon

Jefferies Group’s Myriad Genetics MYGN Stock Holding History

Jefferies Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-85,131
Closed -$2.4M – 2753
2019
Q1 		$2.83M Buy
+85,131
New +$2.59M 0.02% 714
2018
Q3 		– Sell
-6,682
Closed -$250K – 2635
2018
Q2 		$250K Sell
6,682
-511
-7% -$17.3K ﹤0.01% 1932
2018
Q1 		$213K Sell
7,193
-2,426
-25% -$82.1K ﹤0.01% 1943
2017
Q4 		$330K Buy
+9,619
New +$325K ﹤0.01% 1959
2017
Q3 		– Sell
-9,875
Closed -$255K – 2528
2017
Q2 		$255K Sell
9,875
-10,181
-51% -$216K ﹤0.01% 1949
2017
Q1 		$385K Buy
+20,056
New +$355K ﹤0.01% 1724
2015
Q1 		– Sell
-30,950
Closed -$1.11M – 2287
2014
Q4 		$1.05M Sell
30,950
-31,900
-51% -$1.13M 0.01% 955
2014
Q3 		$2.42M Buy
62,850
+61,947
+6,860% +$2.31M 0.02% 657
2014
Q2 		$35K Sell
903
-25,386
-97% -$945K ﹤0.01% 1949
2014
Q1 		$899K Buy
+26,289
New +$814K 0.01% 976
2013
Q4 		– Sell
-16,741
Closed -$423K – 2127
2013
Q3 		$393K Buy
16,741
+16,320
+3,876% +$464K ﹤0.01% 1305
2013
Q2 		$11K Buy
+421
New +$12.2K ﹤0.01% 1756

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jefferies Group's MYGN Position: Q2 2019 in Review

Jefferies Group sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 85,131 shares — an estimated $2.4M sold.

Jefferies Group first reported a position in MYGN in Q2 2013 and held it in 12 quarters. The position peaked at $2.83M in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

  • Jefferies Group reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
  • Jefferies Group sold 85,131 Myriad Genetics shares in Q2 2019, an estimated $2.4M.
  • Jefferies Group first reported a position in Myriad Genetics in Q2 2013 and held it in 12 quarters.
  • Jefferies Group's Myriad Genetics position peaked at $2.83M in Q1 2019.
  • 235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Jefferies Group's 13F filing for Q2 2019, filed 14 Aug 2019.